A new drug is helping families who’ve spent years padlocking fridges, chaining garbage cans, and hiding food as their children with Prader-Willi syndrome deal with unrelenting hunger. But additional progress — and a broader understanding of obesity — is now under threat as the government dismantles the pipeline for promising new research.
Late last year, South Carolina Medicaid approved a class of medications known as GLP-1s to treat obesity, placing it among the few state programs covering these effective but expensive drugs. But access remains limited, even for patients covered by Medicaid, because of stringent prerequisites that must be satisfied before starting the drug.
According to the timeline in the May 12 executive order, prescription drug price reductions would not happen “almost immediately,” but rather could take months or years. And extending the savings to Americans outside federal health insurance programs such as Medicare would likely require congressional action.
While Big Pharma seems ready to weather the tariff storm, independent pharmacists and makers of generic drugs — which account for 90% of U.S. prescriptions — see trouble ahead for patients.
GOP-controlled House committees approved parts of President Donald Trump’s “one big, beautiful bill” this week, including more than $700 billion in cuts to health programs over the next decade — mostly from Medicaid, which covers people with low incomes or disabilities. Meanwhile, Health and Human Services Secretary Robert F. Kennedy Jr. testified before Congress for the first time since taking office and told lawmakers that Americans shouldn’t take medical advice from him. Julie Appleby of KFF Health News, Alice Miranda Ollstein of Politico, and Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico Magazine join KFF Health News’ Julie Rovner to discuss these stories and more.
Michael Kestner, CEO of Pain MD, was convicted of 13 fraud felonies after his company gave patients hundreds of thousands of questionable injections at clinics in Tennessee, Virginia, and North Carolina.
KFF is tracking the Medicaid provisions in the 2025 federal budget bill, including new Medicaid work and verification requirements and a reduction in the expansion match rate for states that use their own funds to cover undocumented immigrants.
Republicans on Capitol Hill are struggling to reach consensus on cutting the Medicaid program as they search for nearly a trillion dollars in savings over the next decade — as many observers predicted. Meanwhile, turmoil continues at the Department of Health and Human Services, with more controversial cuts and personnel moves, including the sudden nomination of Casey Means, an ally of Robert F. Kennedy Jr.’s, to become surgeon general. Anna Edney of Bloomberg News, Maya Goldman of Axios, and Sandhya Raman of CQ Roll Call join KFF Health News’ Julie Rovner to discuss these stories and more. Also this week, Rovner interviews KFF Health News’ Lauren Sausser, who co-reported the latest “Bill of the Month” feature, about an unexpected bill for what seemed like preventive care.
In a new Trump administration executive order, the Secretary of HHS is directed to work with Congress to implement a change in law to delay negotiation of so-called “small molecule” drugs under the Inflation Reduction Act’s Medicare Drug Price Negotiat…
KFF and the Peterson Center on Healthcare examine market trends contributing to rising health costs and identify several potential federal and state policy issues to watch throughout 2025, including high-cost drugs, federal funding cuts, and workforce …
